Research programme: cannabinoid receptor CB1 modulators - Predix Pharmaceuticals
Latest Information Update: 28 Mar 2008
At a glance
- Originator EPIX Pharmaceuticals
- Class
- Mechanism of Action Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity; Pain
Most Recent Events
- 28 Mar 2008 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 28 Mar 2008 Discontinued - Preclinical for Pain in USA (unspecified route)
- 17 Aug 2006 Predix Pharmaceuticals has been acquired and merged into EPIX Pharmaceuticals